Zealand Pharma A/S · OMXCOP:ZEAL
Zealand Pharma A/S — H1 2020 Earnings Presentation
14 slides from Zealand Pharma A/S's earnings presentation, Aug 13, 2020
Slide 1: Interim report for the first half of 2020
Interim report for the first half of 2020 Zealand Pharma August 13, 2020
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the inform
Slide 3: Accelerating U.S. commercial operations & advancing our pipeline
Accelerating U.S. commercial operations & advancing our pipeline Business highlights for H1 2020 and • Announced FDA filing and acceptance of New Drug Application (NDA) for the dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia subsequent events • Completed enrollment in the first
Slide 4: Progressing our business initiatives despite COVID-19
Progressing our business initiatives despite COVID-19 Safety of HCP and patient Research activities Clinical trials our people engagement Taking precautions to Adjusting the way we Continuing enrollment in Staying connected with keep our employees, work so that laboratory- trials; starting to see he
Slide 5: Income statement
Income statement DKK thousand H1 2020 H1 2019 Revenue 233,432 19,918 Gross Margin 205,406 19,734 Research and Development Expense -291,658 -256,910 Sales and Marketing Expense -74,853 0 Administrative Expense -70,665 -35,191 Operating result -230,912 -272,072 Net financial items -9,003 4,794 Result
Slide 6: A strong financial position to support our growing business
A strong financial position to support our growing business Net Operating Expenses Cash position DKK 437.2 million / USD 65.7 million DKK 1.65 billion / USD 247.2 million DKKm DKKm 700 1,800 1,600 600 1,400 500 1,200 400 1,000 300 800 600 200 400 100 200 0 0 2016 2017 2018 2019 1H 2020 2016 2017 201
Slide 7: 2020 financial guidance
2020 financial guidance Net product revenue from the sales of the V-Go wearable insulin delivery device is expected to be within the 2020 2019 range of DKK 150 - 175 DKKm Guidance Realized million for the period beginning on April 2, 2020 Net operating expenses1 950 – 1,000 629 and ending on Decembe
Slide 8: R&D Pipeline
R&D Pipeline Upcoming Product Candidate Partner Indication Pre-clinical Phase 1 Phase 2 Phase 3 Registration Milestones PDUFA Date Dasiglucagon HypoPal® Rescue Pen Severe hypoglycemia March 27, 2021 Q4 2020: Dasiglucagon S.C. Continuous Infusion Congenital hyperinsulinism Phase 3 Readout Dasiglucago
Slide 9: Multiple opportunities with dasiglucagon via different product modalities
We are pursuing multiple opportunities to improve patients’ lives with dasiglucagon via different product modalities Dasiglucagon Novel stable glucagon analog Fast onset-of-action Unique stability in liquid formulation HypoPal® Infusion Dual hormone Adjustable mini dose pen Suitable for multiple ind
Slide 10: Severe hypoglycemia is one of the most feared complications for diabetes patients
Severe hypoglycemia is one of the most feared complications for diabetes patients on insulin therapy1 Our Solution Dasiglucagon HypoPal® – a stable glucagon analog for fast rescue treatment of severe hypoglycemia For illustration only Fast onset of action: Three Phase 3 trials met all primary and ke
Slide 11: Congenital hyperinsulinism (CHI) is an ultra-rare and devastating congenital disorder
Congenital hyperinsulinism (CHI) is an ultra-rare and devastating congenital disorder in newborns Our Solution A potential first-in-class glucagon analog for short- and long-term glycemic stabilization of children with CHI For illustration only Phase 3 trials in children with CHI: • Less hypoglycemi
Slide 12: Short bowel syndrome is a chronic and debilitating disease
Short bowel syndrome is a chronic and debilitating disease affecting up to 40,000 people in the U.S. and Europe1,2 Our Solution Rare and severe disease that impairs intestinal Glepaglutide: a long-acting absorption, diarrhea and GLP-2 analog for treatment of metabolic complications3 short bowel synd
Slide 13: 2020 is a significant year of Zealand
2020 is a significant year of Zealand 5x25 2020 4 2 313 5 commercialized Commercial Late stage assets License Employees products by 2025 foundation and robust partnerships established early pipeline Fully integrated Commercial Three late-stage Boehringer Offices in biotech with U.S. platform in plac
Slide 14: Q&A
Q&A 14